Pfizer Inc, founded in 1849, is dedicated to better health and greater access to healthcare for people and their valued animals. Our purpose is helping people live longer, healthier, happier lives. Our route to that purpose is through discovering and developing breakthrough medicines; providing information on prevention, wellness, and treatment; consistent high-quality manufacturing of medicines, consumer products; and global leadership in corporate responsibility. Every day we help 38 million patients, employ more than 122,000 colleagues, utilize the skills of more than 12,000 medical researchers, and work in partnership with governments, individuals, and other payers for healthcare to treat and prevent illnesses—adding both years to life, and life to years.
Pfizer in China
In the 1980's, following in tow with the progress of China's opening and reform, Pfizer entered the China market with a long term vision for development. Pfizer now has three business segments in China: pharmaceutical, capsule and animal health products.
Pfizer is committed to the long-term development of China's healthcare environment and strives to improve Chinese healthcare through continuing to introduce, manufacture and market many of our leading innovative medications. We are distinctive in our pursuit to make these available to Chinese patients at the same time of their introductions globally. With an unequalled product portfolio, Pfizer China maintains category leadership in the therapeutic areas of cardiovascular disease, endocrinology, neuroscience, arthritis and other inflammatory diseases, infectious disease, urology, ophthalmology and oncology. The depth of our reach has enabled us to hold the highest percentage of market share of any foreign pharmaceutical company in China.
With the support of various levels of the Chinese government and the public sectors, Pfizer's operations in China have developed rapidly. With an investment of more than US$500 million, Pfizer is one of the largest foreign pharmaceutical enterprises in China. Pfizer successfully established state-of-the-art plants in Dalian, Suzhou and Wuxi. The Dalian plant was the first in China to receive GMP certification. As part of a globally integrated Pfizer Global Manufacturing organization, we are committed to making "Quality" one of our core values and to producing products that fit our values. Meanwhile, we continue to pursue innovation, improve product costs, and maintain the industry's highest environmental, health and safety standards. Pfizer's success in China has solidified our faith in the achievability of the long-term development of China's healthcare environment. Pfizer opened many branch offices in most major cities throughout China. In 1997, Pfizer established its China management center in Beijing; in 2004, established the Pfizer Investment Co.,Ltd. and the Pfizer China Regional Headquarters in Shanghai to integrate and oversee all of Pfizer's China operations. These milestones have made China a priority in Pfizer's global strategy. In the coming five years, Pfizer plans to introduce 15 innovative products in the China market, three times the number of products launched in the past five years. This will further serve to benefit Chinese patients and contribute significantly to all of society.